Core Viewpoint - Elicio Therapeutics is making significant progress in developing its lead immunotherapy candidate, ELI-002 7P, for treating KRAS-mutant pancreatic cancer, with an event-driven primary disease-free survival analysis expected in the first half of 2026 [2][5][12] Financial Performance - In 2025, the company reported a net loss of $39.5 million, a decrease from $51.9 million in 2024, with a net loss per share of $2.58 compared to $4.25 in the previous year [8][11] - Research and development (R&D) expenses for 2025 were $24.9 million, down from $33.7 million in 2024, primarily due to lower clinical costs as patients progressed into the observation phase of the Phase 2 study [7][11] - General and administrative (G&A) expenses increased to $12.8 million in 2025 from $11.3 million in 2024 [7][11] - Cash and cash equivalents as of December 31, 2025, were $18.6 million, compared to $17.6 million at the end of 2024, with projected cash runway extending into Q3 2026 [8][9][14] Clinical Development - The Phase 2 AMPLIFY-7P trial is ongoing, with fewer disease progressions and deaths observed than projected, reinforcing confidence in ELI-002 7P's potential [2][5][6] - Evidence of antigen spreading to patient-specific neoantigens beyond mKRAS has been reported, indicating the potential durability of the immune response [6] - The company plans to request an End-of-Phase 2 meeting with the FDA to finalize the Phase 3 trial design for ELI-002 7P following the primary DFS analysis [12] Upcoming Milestones - The event-driven primary DFS analysis for the Phase 2 AMPLIFY-7P study is anticipated in the first half of 2026 [5][6] - Elicio will present updates on the ELI-002 platform and AMPLIFY-7P trial at upcoming conferences, including the World Vaccine Congress and the AACR Annual Meeting [6]
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates